Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
NCT04573231
Summary
The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor (AR)-positive metastatic breast cancer, and to determine its role in resistance to the anti-androgen, bicalutamide. The investigators hypothesize that PSMA expression will correlate with resistance to anti-androgen therapies, as has been documented in prostate cancer, and this can be used to select patients most likely to benefit from these therapies in future clinical trials. 15 people with HER2-negative, AR-positive metastatic breast cancer will be enrolled and be on study for about 3 days.
Eligibility
Inclusion Criteria: * Patients diagnosed with metastatic HER2-negative breast cancer AR expression of ≥ 10% Exclusion Criteria: * Other (non-breast) known active malignancy. Participants with previously treated cancers which are in remission or have no evidence of disease are eligible. * Unable to lie flat during or tolerate PET/CT * Participants with any medical condition or other circumstances that, in the opinion of the investigator, compromise the safety or compliance of the subject to produce reliable data or completing the study * Women of childbearing potential must not be pregnant or breast feeding (pregnancy test negative within 7 days prior to PET/CT
Conditions4
Interventions1
Locations1 site
Find trials near these locations
Related trials
- Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy — National Cancer Institute (NCI)
- Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor — National Cancer Institute (NCI)
- Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL — National Cancer Institute (NCI)
- Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan — Brigham and Women's Hospital
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT04573231